LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
Goshua G, Pine AB, Meizlish ML, Chang C-H, Zhang H, Bahel P, et al
Glutathione synthetase deficiency
Those most at risk include vegans and vegetarians, people with digestive conditions such as Crohn's disease, coeliac disease or IBS, those taking long-term metformin or proton pump inhibitors, older adults whose ability to absorb B12 through the gut declines naturally with age, those with pernicious anaemia, and anyone with a history of chronic alcohol use
He also stresses the importance of consulting with a licensed healthcare provider before starting any type of injectable regimen
Lancet Regional Health - Europe